A method of treating a vascular disease, vascular injury or vascular inflammation in a mammal, comprising administering to the mammal an isolated human soluble receptor for advanced glycation end products (sRAGE) polypeptide comprising a mammalian post-translation modification, wherein the amino acid sequence of the sRAGE polypeptide is at least 95% identical to SEQ ID NO: 4 and the mammalian post-translation modification comprises mammalian N-glycosylation, thereby treating the vascular disease, vascular injury, or vascular inflammation in the mammal.
A method of treating a vascular disease, vascular injury or vascular inflammation in a mammal, comprising administering to the mammal an isolated human soluble receptor for advanced glycation end products (sRAGE) polypeptide comprising a mammalian post-translation modification, wherein the amino acid sequence of the sRAGE polypeptide is at least 95% identical to SEQ ID NO: 4 and the mammalian post-translation modification comprises mammalian N-glycosylation, thereby treating the vascular disease, vascular injury, or vascular inflammation in the mammal.<br>
正在翻译中..